Charles Ryan, MD
Charles Ryan, MD
Professor of Clinical Medicine and Urology
Program Leader, Genitourinary Medical Oncology
UCSF Helen Diller Comprehensive Cancer Center
San Francisco, CA

Dr. Ryan’s Disclosure:
Charles Ryan, MD has disclosed having financial arrangements or affiliations with the following commercial interest(s) whose products or services may be mentioned in this activity.
Members, Speakers Bureau: Janssen, Astellas
Consultant: Medivation, Takai, Astra Zeneca

Evan Y. Yu, MD
Evan Y. Yu, MD
Program Operation Specialist Genitourinary Oncology
University of Washington
Seattle Cancer Care Alliance
Seattle, WA

Dr.Yu’s Disclosure:
Evan Y. Yu, MD has disclosed having financial arrangements or affiliations with the following commercial interest(s) whose products or services may be mentioned in this activity.
Research Grant: Amgen, Astellas, Bayer, Dendreon, Genentech/Roche, Imclone, Lilly, Merck
Consultant: Astra Zeneca, Bayer, Dendreon, EMD Serano, Genentech/Roche, Janssen, Lilly, Merck

Accredited By

Co-provided By

This activity is co-provided by Rush University and PleXus Communications.

Program Endorsers

The Association of VA Hematology/Oncology (AVAHO) and the Society of Government Service Urologists (SGSU)

Activity Details

Credit Type: AMA, ANCC, ACPE
Credit Amount: 1.0
Release Date: March 7, 2017
Expiration Date: March 6, 2018
Estimated Time to Complete Activity: 60 minutes
Registration Required: No
Fee for Activity: There is no fee for participating in this activity.

Activity Description

This activity will provide the most up-to-date information on current therapeutic approaches, promising advances, and nursing considerations in treating patients with prostate cancer.

Educational Objectives

After completing this program, participants should be able to:

  1. Identify best practices for integrating current available treatment options for advanced prostate cancer, including immunologic therapies, new secondary hormonal agents, chemotherapy, and radiopharmaceuticals
  2. Outline considerations for combining and sequencing current and emerging therapies in the management of patients with advanced prostate cancer
  3. Distinguish among the molecular mechanisms involved in the pathology of CRPC as it relates to the genetic landscape of prostate cancer and personalized medicine

Target Audience

Healthcare providers who are involved with the treatment of patients with prostate cancer

Conflict of Interest Policy / Disclosure Statement

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Accreditation Information

Rush University Medical Center is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Rush University designates this enduring activity for one (1) Continuing Education credits. This activity will fulfill Category 1 contact hour requirements for pharmacology for ANCC certified advanced practice nurses.

This program is approved for 1.0 hours (0.1 CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
The UPN number for this activity is 0622-0000-17-L01-P.

Requirements for Successful Completion

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Instructions for Receiving Credit

Participants must complete and submit the online CE evaluation form at the conclusion of the activity and achieve a passing score of 75% or better. Certificates will be generated upon completion and submission of the evaluation form.

Statement of Commercial Support

This activity is supported by educational grants from Astellas Scientific and Medical Affairs, Inc. and Medivation, Inc., a Pfizer company, Bayer HealthCare, and Janssen Biotech, Inc.

Disclaimer Statement / Disclosure of Unlabeled Use

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Rush University, AVAHO, SGSU, PleXus Communications, and/or the commercial supporters. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Rush University, AVAHO, SGSU, PleXus Communications and/or the commercial supporters. Rush University’s ANCC accreditation status does not imply endorsement by Rush or ANCC of any commercial products displayed in conjunction with this activity. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Contact Information for Questions about the Activity

Hardware / Software Requirements

Our educational activities are available on Mac, PC, and Multi-Touch devices. For the best online experience, we recommend using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox or Safari.

Depending on your browser of choice, additional software, such as Adobe Reader®, may be required.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.